Podcasts about breakthroughs

Igor tells the story of losing a 100,000-subscriber AWeber account overnight. What felt like disaster at the time became the catalyst for innovation, resilience, and ultimately, growth. He explains how great entrepreneurs turn setbacks into breakthroughs, and how you can too.

John Casmon interviews James Faillettaz, a Minneapolis-based investor who scaled from five units in a spreadsheet to restructuring an entire real estate company after an ambitious early strategy nearly collapsed. James shares how he over-hired, over-built, and over-extended while trying to operate like a Silicon Valley startup—then completely rebuilt his structure with the help of mentors and mastermind groups. He walks through how he created new momentum by taking over distressed properties through master lease with purchase option agreements, ultimately acquiring 101 units with zero money down. James also breaks down the value he brings to sellers, how he structures creative deals, and the lessons he learned from reinventing his model the hard way. James FaillettazCurrent role: Founder, Verus Praedium Holding / Revolution Renting, Investing, Construction & RealtyBased in: Minneapolis–St. Paul, MinnesotaSay hi to them at: https://veruspraediumholding.com Alternative Fund IV is closing soon and SMK is giving Best Ever listeners exclusive access to their Founders' Shares, typically offered only to early investors. Visit smkcap.com/bec to learn more and download the full fund summary. Join us at Best Ever Conference 2026! Find more info at: https://www.besteverconference.com/  Join the Best Ever Community  The Best Ever Community is live and growing - and we want serious commercial real estate investors like you inside. It's free to join, but you must apply and meet the criteria.  Connect with top operators, LPs, GPs, and more, get real insights, and be part of a curated network built to help you grow. Apply now at⁠ ⁠⁠⁠www.bestevercommunity.com⁠⁠ Podcast production done by⁠ ⁠Outlier Audio⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Habitat Podcast #359 - In today's episode of The Habitat Podcast, we are back at the northern 70 with the HP crew for another year of deer camp! We discuss: Growth comes from showing up, even when you don't feel ready The land teaches you—if you're willing to listen Failures shape you more than the easy seasons Priorities shift as life, family, and purpose evolve Breakthroughs often come right after frustration Learning your property is a lifelong process Small moments outdoors can reset your whole mindset Progress happens through imperfect reps, not perfection Knowing what matters makes every decision clearer Hunting becomes deeper when it's tied to who you're becoming And So Much More! Shop the new Amendment Collection from Vitalize Seed here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://vitalizeseed.com/collections/new-natural-amendments ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ PATREON - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon - Habitat Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Brand new HP Patreon for those who want to support the Habitat Podcast. Good luck this Fall and if you have a question yourself, just email us @ info@habitatpodcast.com -------------------------------------------------------------------------- ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon - Habitat Podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Latitude Outdoors - Saddle Hunting: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/hplatitude⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Stealth Strips - Stealth Outdoors: Use code Habitat10 at checkout ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/stealthstripsHP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Midwest Lifestyle Properties - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/3OeFhrm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Vitalize Seed Food Plot Seed - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/vitalizeseed⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Down Burst Seeders - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/downburstseeders⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 10% code: HP10 Morse Nursery - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://bit.ly/MorseTrees⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 10% off w/code: HABITAT10 Packer Maxx - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://bit.ly/PACKERMAXX⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ $25 off with code: HPC25 First Lite - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bit.ly/3EDbG6P⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LAND PLAN Property Consultations – HP Land Plans: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LAND PLANS⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Leave us a review for a FREE DECAL - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://apple.co/2uhoqOO⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Morse Nursery Tree Dealer Pricing – info@habitatpodcast.com Habitat Podcast YOUTUBE - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UCmAUuvU9t25FOSstoFiaNdg⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Email us: info@habitatpodcast.com habitat management / deer habitat / food plots / hinge cut / food plot Learn more about your ad choices. Visit megaphone.fm/adchoices

Astrology and Tarot from two grounded Earth signs! We're here to show you the energies so you can embrace them in your own way. In this episode of the Cosmic Energy Report, Emily celebrate's a major milestone, Episode 100 of Things That Make You Go Woo! Andrea joins and they dive into the fiery, fast-moving energy of Sagittarius Season 2025. They reflect on the emotional depths of Scorpio season, the heavy retrogrades, and the transformational eclipse cycle that set the stage for this moment of renewal. Emily walks listeners through the key transits of the month, including Mercury retrograde and its forward turn, Venus entering Sagittarius, Saturn and Neptune's movements, the Gemini Super Full Moon, and the Sagittarius New Moon, as well as the influence of Black Moon Lilith and what it reveals about collective feminine power, truth-telling, and boundaries. Andrea brings in powerful tarot cards for each week of the season, highlighting themes of creativity, material success, emotional fulfillment, and grounded intuition. From The Empress to the Ten of Pentacles, the Seven of Wands to Judgment, the cards carry a distinctly feminine current that mirrors the skies and affirms that a new cycle is truly beginning. Together, Emily and Andrea explore how these energies may show up emotionally, relationally, and creatively, especially as we shift from a 9-year to a 1-year. They emphasize the importance of community, genuine self-expression, and sustainable pacing so we don't burn out in the holiday rush. Tune in for a heartfelt, fire-lit exploration of transition, and hear why Sagittarius season is the perfect time to test-drive your next evolution while holding your boundaries and embracing the cosmos' expansive invitation.     Show Notes: 00:00 Welcome and Milestone Celebration 01:51 Reflecting on Scorpio Season 06:12 Transitioning to Sagittarius Energy 16:52 Astrological Insights and Predictions 17:04 Embracing Creative Energy 20:24 Navigating Mercury Retrograde 23:12 Building Foundations and Emotional Growth 31:17 Facing Challenges and Staying Grounded 42:05 Breakthroughs and Emotional Fulfillment 42:26 Balancing Material and Emotional Fulfillment 43:44 Navigating Sagittarius Season 44:34 Holiday Season Reflections 45:35 Trusting the New Reality 46:09 Astrological Influences and Emotional Gut Checks 52:20 Embracing the Queen of Pentacles Energy 01:01:47 Judgment and Self-Reflection 01:15:36 Artistic Endeavors and Community Support   Looking for personalized guidance? Visit emilyandherstars.com for readings, workshops, and updates. ✨ Subscribe, rate, and review Things That Make You Go Woo to help others find the magic. ✨ Share this episode with a friend who'd love some Scorpio Season clarity. Connect with Emily Join the Cards + Cosmos Club: https://www.emilyandherstars.com/shop/p/2025cardscosmos Newsletter + Calendar Download: https://emilyandherstars.myflodesk.com/newslettersignup Bookings & Website: https://www.emilyandherstars.com/services Instagram & Threads: @emilyandherstars Connect with Andrea Newsletter: https://www.andreamccallumservices.com/newsletter-signup Remote Recharges: https://www.andreamccallumservices.com/remote-recharges Direct to Bookings: https://www.andreamccallumservices.com/sessions Website: https://www.andreamccallumservices.com/ Instagram: @concreteandcrystals

In this episode of the Cosmic Energy Report, Emily and Andrea celebrate a major milestone - Episode 100 of Emily's podcast, Things That Make You Go Woo - while diving into the fiery, fast-moving energy of Sagittarius Season 2025. They reflect on the emotional depths of Scorpio season, the heavy retrogrades, and the transformational eclipse cycle that set the stage for this moment of renewal. With humor, honesty, and their signature practical-mystical blend, they walk listeners through the astrological transits that ignite momentum, clarity, and a sense of possibility after a long stretch of inner work. Andrea brings in powerful card pulls for each week of the season, weaving in themes of grounding, confidence, collaboration, emotional fulfillment, and stepping into new identities with courage. From the Empress to the Ten of Pentacles, from the Seven of Wands to Judgment, this month's tarot archetypes affirm that a new cycle is truly beginning. Emily explores the planetary shifts shaping the month including Venus entering Sagittarius, Saturn stationing direct, Mercury regaining forward motion, the Gemini Super Full Moon, Neptune's direct station, and the Sagittarius New Moon. Together, they parse out how these collective energies may show up emotionally, relationally, and creatively and how to pace ourselves so we don't burn out in the holiday rush.  Tune in for a heartfelt, fire-lit exploration and to hear why Sagittarius season is the perfect time to test-drive your next evolution. Hold your boundaries while you embrace the shifts, and enjoy Sagittarius's expansive energy!    Show Notes 00:00 Welcome and Milestone Celebration 01:51 Reflecting on Scorpio Season 06:12 Transitioning to Sagittarius Energy 16:52 Astrological Insights and Predictions 17:04 Embracing Creative Energy 20:24 Navigating Mercury Retrograde 23:12 Building Foundations and Emotional Growth 31:17 Facing Challenges and Staying Grounded 42:05 Breakthroughs and Emotional Fulfillment 42:26 Balancing Material and Emotional Fulfillment 43:44 Navigating Sagittarius Season 44:34 Holiday Season Reflections 45:35 Trusting the New Reality 46:09 Astrological Influences and Emotional Gut Checks 52:20 Embracing the Queen of Pentacles Energy 01:01:47 Judgment and Self-Reflection 01:15:36 Artistic Endeavors and Community Support   Connect with Andrea Newsletter: https://www.andreamccallumservices.com/newsletter-signup Remote Recharges: https://www.andreamccallumservices.com/remote-recharges Direct to Bookings: https://www.andreamccallumservices.com/sessions Website: https://www.andreamccallumservices.com/ Instagram: @concreteandcrystals

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory approvals, and strategic shifts that are reshaping the industry.Starting with Regeneron, the company's ophthalmic drug Eylea HD has recently secured two FDA approvals. These endorsements not only grant a new indication but also introduce a more flexible dosing regimen. This positions Eylea HD competitively against Roche's Vabysmo, highlighting the importance of regulatory navigation and strategic positioning in the pharmaceutical sector. These approvals come after extensive negotiations with both the FDA and third-party manufacturers, emphasizing the intricate processes involved in bringing a drug to market.In oncology, Bayer has achieved an accelerated FDA approval for Hyrnuo, a treatment targeting HER2-mutated non-small cell lung cancer. This move allows Bayer to challenge Boehringer Ingelheim's Hernexeos, underscoring the fiercely competitive nature of the oncology market. Such advancements are driven by innovative treatments that address specific genetic mutations in cancer patients, reflecting a broader trend towards precision medicine.Meanwhile, Moderna is investing heavily in mRNA production capabilities with a new $140 million facility in Norwood, Massachusetts. This development underscores Moderna's commitment to mRNA technology, which gained significant attention during the COVID-19 pandemic. The facility aims to establish robust domestic manufacturing infrastructures to mitigate supply chain vulnerabilities—a critical move considering recent global disruptions.Novartis is also making headlines with its plans for a flagship production hub in North Carolina. This expansion is expected to create 700 jobs and expand its manufacturing footprint by 700,000 square feet, highlighting Novartis's strategic emphasis on scaling up operations to meet growing demands and enhance production efficiency.In another strategic collaboration, Antheia has joined forces with Teva's TAPI division to enhance the commercialization prospects for its biosynthetic pipeline. This alliance marks a significant step toward advancing biologically derived pharmaceuticals, promising to revolutionize drug production through more sustainable and scalable alternatives to traditional chemical synthesis.On the regulatory front, Merck has received broad EU approval for a subcutaneous formulation of Keytruda. This development could significantly expand Keytruda's market reach across Europe, demonstrating how regulatory agility can extend drug lifecycles and maximize therapeutic impact across diverse patient populations.Compliance challenges remain prevalent, as illustrated by Pfizer and Tris Pharma's settlement of allegations related to ADHD medication Quillivant's quality control issues for $41.5 million. This case highlights ongoing efforts to ensure stringent quality standards within pharmaceutical manufacturing processes.Abbott is expanding its diagnostics portfolio through a $23 billion acquisition of Exact Sciences, known for its Cologuard colorectal cancer test. This acquisition indicates a strategic shift towards enhancing diagnostic capabilities alongside therapeutic offerings—a trend increasingly evident in holistic healthcare solutions.GSK is embarking on a $7 billion collaboration with biotechs Quotient and Profound through Flagship Pioneering. This partnership aims to leverage novel protein and genomic technologies to drive innovation in drug discovery and development, illustrating the industry's focus on integrating advanced biotechnological insights into traditional pharmaceutical frameworks.These developments collectively underscore crSupport the show

Send us a textIt's Therapy Thursday!!The air still hums from a room that felt brave enough for everyone. We unpack what happened at our women's conference where a Muslim practitioner, a Christian voice, and someone who practices magic shared a stage without defensiveness—and why safety, not sameness, made the healing real. The stories that poured out, the tissues that ran thin, and the look on faces walking out lighter reminded us: when people feel held, they release what they no longer need.From that high-frequency moment, we trace the everyday threads that carry healing forward. Snow the next morning felt like a season turning, and two fearless kittens named Marco and Polo taught us how to enter change with curiosity instead of fear. We talk about service that restores dignity—hotel rooms for unhoused families, turkey giveaways—and how helping becomes a place to practice our humanity. We also wrestle with bringing kids into service: intention, consent, and the heart posture that keeps respect at the center.Parenting and reparenting meet in real time as many of us teach emotional skills we never received while rebuilding our own. We talk boundaries that protect home, the risk of over-giving, and the relief that comes with aging into acceptance over performance. Then we zoom out to mental health and the power of labels, revisiting the Rosenhan study to ask for nuance in diagnosis without dismissing real care. The practical medicine we keep returning to is gratitude: one line in a journal, one quiet thank you, one mindful breath that anchors the day.Come for the conference recap; stay for the honest look at community, service, parenting, and the small daily practices that make healing stick. If the episode resonates, subscribe, share it with a friend who needs encouragement, and leave a review to help others find this space. What's one thing you're grateful for today?Support the showHost Candace PatriceCo-host Janet Halevisit the website at https://www.essentialmotivation.com/visit the store at https://shopessentialmotivation.com/Instagram instagram.com/essentialmotivationllc visit Janet's website https://haleempowermentllc.com/To be a guest on our show email me at candacefleming@essentialmotivation.comIn the subject line put EMH Guest Suicide Prevention Lifeline 988Music by Lukrembo: https://soundcloud.com/lukremboProvided by Knowledge Base: https://bit.ly/2BdvqzN

Lynnell celebrates a historic day for Maryland Men's Basketball: 5-star forward Baba Oladotun commits for next season, and the current Terps squad, short-handed, secures an overtime win over Mount St. Mary's thanks to David Coit's record-setting 41-point performance at the Xfinity Center.

The year isn't over yet! In today's episode, we're diving into 2 Kings 7, where God brought a sudden breakthrough for Samaria. This story reminds us that no matter how things look, God is still able to turn things around, suddenly!If you've been waiting, praying, or wondering when your breakthrough will come, this is your encouragement: the year isn't over yet and God is still moving!

PEOPLE HEAL WHERE THEY FEEL SAFE. You can't rush transformation; you can only make it safe to happen. Emotional safety isn't soft—it's strategic. Clients won't explore what feels dangerous, but they will open up where peace is modeled. Key Takeaways: Safety begins with your tone, pace, and posture. A calm presence regulates the entire session. Validation is more powerful than advice. Action Guide: In your next session, slow your pace and soften your tone. Ask yourself, “Would I feel safe being coached by me right now?” Read the Life Coach Blog Become a S&S Life Coach Join the Coaching FB Community —> HERE Find me @coachlauramalone on IG —> HERE Your 5 star review on Apple Podcasts means a ton✨

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show

Dr Ellie Cannon is joined by Lord Bethell, Member of the House of Lords, and Hetal Naik, Primary Care Lead at Pfizer UK, to discuss the evolving role of vaccines in the UK's prevention strategy and how to help improve equitable vaccine access. PP-UNP-GBR-13788 / November 2025 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textIn this raw solo episode, Jonathan Cinelli opens up about one of the most intense breakdowns of his life and the breakthrough it created. He talks openly about emotional extremes, guilt, shame, and the reality of being a leader who's still human. From stepping away to reset, to grounding practices, to the conversations that matter most, this episode is a reminder that none of us are alone.If you've ever felt like life hit too hard or you're carrying more than you can hold, this one's for you.Breakdowns don't mean failure; they create space for evolution.Support the show

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of the industry, exploring significant scientific advancements, regulatory changes, clinical trial outcomes, and strategic investments that are shaping the future of healthcare.Starting with strategic investments, Regeneron is making a bold move with a $2 billion investment to transform a former magazine factory in Saratoga Springs, New York, into a state-of-the-art drug manufacturing plant. This investment reflects a broader industry trend towards enhancing domestic manufacturing capabilities to ensure supply chain resilience. Similarly, CSL is channeling $1.5 billion into U.S. plasma-based manufacturing over the next five years. These investments are critical as plasma-derived therapies continue to play a vital role in treating various conditions, necessitating robust manufacturing infrastructure to meet growing demand.In clinical research, Merck's Winrevair has shown promising results in a proof-of-concept study for heart failure patients. This advancement highlights ongoing efforts to address one of the leading causes of morbidity and mortality worldwide—heart failure. The study paves the way for further exploration of activin signaling inhibitors in cardiovascular therapies.On the regulatory front, Eli Lilly has expanded its market reach with the approval of its Alzheimer's medication for distribution in India. This milestone represents progress in tackling the global Alzheimer's disease burden, an ailment that presents significant challenges to healthcare systems worldwide.The FDA's recent critique of AstraZeneca's Farxiga advertisement underscores the importance of accuracy in pharmaceutical marketing. The agency's concerns about potential misleading impressions emphasize ongoing regulatory vigilance to align marketing practices with approved therapeutic uses and ensure patient safety.Shifting to business strategies, Zymeworks' transition towards becoming a 'royalty-driven organization' marks an evolution in biotech business models. By leveraging successful licensing frameworks, Zymeworks aims to enhance revenue streams while focusing on innovation without the traditional constraints of direct commercialization.In cardiovascular therapeutics, Cytokinetics is positioning itself strategically by funding a heart registry, signaling an intensifying competitive landscape as companies vie for leadership in this critical area of healthcare.Roche's development of giredestrant, an oral selective estrogen receptor degrader (SERD), has achieved success in a phase 3 adjuvant breast cancer trial. This positions Roche to capture an unoccupied niche within the competitive breast cancer treatment market and highlights a trend towards targeted therapies with potentially significant patient outcomes.Addressing side effects associated with GLP-1 receptor agonists, Vanda Pharmaceuticals is making strides with tradipitant to mitigate nausea and vomiting induced by Wegovy. As GLP-1 agonists gain traction for their metabolic benefits, adjunct therapies addressing side effects are becoming increasingly pertinent.In digital health initiatives, Humana's collaboration with Epic aims to automate insurance verification and patient check-ins, aligning with federal interoperability goals. This represents a broader industry shift towards digital solutions designed to streamline administrative processes and enhance patient experience.Meanwhile, Lonza's expansion at its Stein facility in Switzerland underscores ongoing capacity-building efforts among contract development and manufacturing organizations (CDMOs). Such expansions are crucial as they provide biopharmaceutical companies with the neSupport the show

Find me, Granger Forson, at www.bizsmart-gloucestershire.co.uk or connect with me on LinkedIn.   This episode of ScaleUp Radio features Michael Colling-Tuck, founder of Agency Bristol, a specialist marketing agency helping medical and technology innovators reach both patients and healthcare professionals. With over twenty years in healthcare, Michael has seen how even the most brilliant inventions can fail if no one knows they exist. His agency bridges that critical gap, giving groundbreaking products a fighting chance to reach the people whose lives they can transform.   What makes Michael's story stand out is the combination of deep industry experience, genuine humility, and the relentless curiosity of a founder who has seen the highs and lows of scaling. From watching masterclass marketing moments in China to almost getting it wrong twice with his own cash flow, Michael's honesty about resilience, learning, and leadership gives listeners a real and relatable founder story.   He shares how Agency Bristol crafts campaigns that empower advocates, surgeons, clinicians, and patients, to become the best storytellers for new technologies. It's a blend of creativity, structure, and empathy that transforms technical ideas into powerful messages that resonate with real people.   Whether you're a startup founder or a seasoned business leader, this conversation is a lesson in balancing vision with reality. Michael shows that success doesn't just come from clever campaigns, but from finding joy in the grind, trusting your team, and always learning from the journey.   To ensure you don't miss any inspirational future episodes do subscribe to ScaleUp Radio wherever you like to listen to your podcasts.   So, let's now dive into the inspiring journey of innovation, resilience and purpose with Michael Colling-Tuck.   Scaling up your business isn't easy, and can be a little daunting. Let ScaleUp Radio make it a little easier for you. With guests who have been where you are now, and can offer their thoughts and advice on several aspects of business. ScaleUp Radio is the business podcast you've been waiting for. If you would like to be a guest on ScaleUp Radio, please click here: https://bizsmarts.co.uk/scaleupradio/kevin   Book a call with Granger - 30 minutes value add conversation for Business owners with Staff. https://api.goexela.com/widget/bookings/catchupgrangerugx7zl   You can get in touch with Kevin & Granger here: kevin@biz-smart.co.uk grangerf@biz-smart.co.uk   Kevin's Latest Book Is Available! Drawing on BizSmart's own research and experiences of working with hundreds of owner-managers, Kevin Brent explores the key reasons why most organisations do not scale and how the challenges change as they reach different milestones on the ScaleUp Journey. He then details a practical step by step guide to successfully navigate between the milestones in the form of ESUS - a proven system for entrepreneurs to scale up. More on the Book HERE - https://www.esusgroup.co.uk/   Michael can be found here: https://www.agencybristol.com/ https://www.linkedin.com/in/michael-colling-tuck-48529020/   Resources: Why People Don't Buy Things by Harry Washburn - https://uk.bookshop.org/p/books/why-people-don-t-buy-things-five-proven-steps-to-connect-with-your-customers-and-dramatically-improve-your-sales-harry-washburn/43f9c7d071d7ddbc?ean=9780738201573&next=t Black Box Thinking by Matthew Syed - https://uk.bookshop.org/p/books/black-box-thinking-growth-mindset-and-the-secrets-of-high-performance-matthew-syed/2e1b2c9c68295eb5?ean=9781399830379&next=t Oversubscribed by Daniel Priestley - https://uk.bookshop.org/p/books/oversubscribed-how-to-get-people-lining-up-to-do-business-with-you-daniel-priestley/3262406?ean=9780857088253&next=t Shogun by James Clavell - https://uk.bookshop.org/p/books/shogun-book-one-of-the-asian-saga-the-book-that-inspired-the-emmy-bafta-and-golden-globe-award-winning-tv-show-james-clavell/17dcf2869a8b1584?ean=9780340766163&next=t Crystal Palace Podcast - https://www.cpfc.co.uk/palace-tv/palace-podcast/ Diary of a CEO podcast - https://stevenbartlett.com/doac/ Totally Football podcast - https://www.nytimes.com/athletic/podcast/200-the-totally-football-show/ Michael Colling-Tuck podcast - https://open.spotify.com/embed/episode/5OvrvVSySrhTXBJ6EalzY4?utm_source=generator&t=0 Spark app - https://sparkmailapp.com/ WhatsApp - https://www.whatsapp.com/?lang=en Shazam - https://www.shazam.com/    

In this episode, Chandra and Paul cover the latest JD Edwards (JDE) product updates, focusing on the recent release of tools and applications Update 26. They discuss the significance of aligning release numbers for simplicity, the nature of maintenance packs, and the importance of stability over rushing enhancements. The conversation then turns to enterprise automation, specifically the use of the process modeler to identify bottlenecks and drive adoption. The hosts emphasize the need for deeper analysis beyond surface-level process mapping and encourage collaboration between IT and business units to uncover root causes and find lasting solutions. Both hosts highlight the value of continuous learning, empowering teams to explore new tools, and partnering with business stakeholders for successful implementation. 05:11 Empowering Customers Through New Capabilities 08:44 The Challenge Behind Product Adoption 13:27 From Bottlenecks to Breakthroughs 15:20 Partnering for Adoption 23:48 Identifying Blind Spots 27:32 Midwesternism of the Day Resources: Learn more about Enterprise Automation and how to get started, implement, and use on LearnJDE: https://docs.oracle.com/cd/E84502_01/learnjde/enterprise-automation.html# If you have concerns or feedback on this episode or ideas for future episodes, please contact us at thejdeconnection@questoraclecommunity.org

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and kill" bifunctional small molecule platform, is poised to enhance J&J's prostate cancer pipeline significantly. It underscores J&J's commitment to expanding its oncology portfolio through innovative platforms designed to improve therapeutic outcomes. The move highlights a broader industry trend toward personalized medicine and targeted cancer therapies, which are becoming pivotal in improving patient care.In another domain of cancer treatment, Nuvalent has unveiled promising Phase 1/2 data for its candidate neladalkib, which could position the company as a formidable competitor to Pfizer's established lung cancer drug, Lorbrena. The promising data might expedite regulatory discussions with the FDA, potentially leading to an accelerated approval process. This development illustrates the competitive landscape in oncology, where firms strive to introduce novel therapies with improved efficacy and safety profiles.The field of antibody-drug conjugates (ADCs) is also experiencing significant advancements. A San Diego-based biotech has secured $120 million in funding to develop a best-in-class ADC formula, with support from Merck & Co. This initiative aims to refine the precision and efficacy of ADCs by delivering cytotoxic agents directly to cancer cells while minimizing collateral damage to healthy tissues. Such innovations are crucial as they represent a new frontier in targeted cancer therapy.In terms of financial activities, Artios Pharma's successful $115 million Series D funding round is set to bolster its clinical efforts in exploring DNA damage response inhibitors for cancer treatment. These inhibitors target cancer cells' ability to repair DNA damage, holding potential for more effective therapies against resistant cancer types. Meanwhile, Sofinnova Partners' €650 million raise for biotech and medtech investments amid a volatile economic environment underscores continued investor confidence in life sciences despite market uncertainties.Bayer is making strategic moves in China by opening an incubator in Beijing. This facility will host local biopharma companies such as Suzhou Puhe Biopharma and Beijing Youngen Technology, fostering innovation and collaboration within China's burgeoning biotech landscape. Such initiatives reflect global efforts to leverage regional strengths and foster cross-border collaborations.On the operational side, Nxera Pharma is restructuring its workforce by laying off 15% of its staff as part of a strategic pivot towards profitability. This decision mirrors broader industry trends where companies refocus resources on core projects to streamline operations and enhance financial stability.A recent study has highlighted the impact of NIH grant cuts on clinical trials across the United States. Over 383 trials involving more than 74,000 patients have been disrupted due to funding terminations under the current administration. This situation raises concerns about the sustainability of clinical research funding and its implications for ongoing medical advancements.Jazz Pharmaceuticals has reported practice-changing Phase 3 results for its HER2-targeted drug Ziihera for gastroesophageal adenocarcinoma. These findings reaffirm Jazz's confidence in positioning Ziihera as a preferred first-line treatment option for HER2-positive cancers, poSupport the show

- Brighteon Books and Photonic Computing (0:00) - Demonstration of the Book Engine (3:57) - Choosing the Tone and Research Sources (7:02) - The 20 Delusions Shaping U.S. Geopolitics (8:56) - Corporate Bankruptcies and Weight Loss Injections (20:25) - Photonic Quantum Chips and China's Leadership (24:32) - The Photonic Singularity and Future Implications (40:35) - The 20 Delusions of the United States (42:51) - The Role of Sanctions and Public Opinion (47:21) - The Future of the U.S. and Global Perception (56:42) - The Jesus Way Podcast and Christian Reform (1:08:38) - Second Peter and the Authenticity of the Bible (1:16:54) - Personal Testimony and Spiritual Philosophy (1:23:55) - Upcoming Virtual Summit on Christ Consciousness (1:25:57) - Decentralization and Personal Responsibility in Faith (1:28:52) - The Role of Animal Sacrifice in Religious Corruption (1:31:21) - The Essenes and the Rejection of Temple Cult Practices (1:39:30) - The Connection Between Nazarene Christianity and Islam (1:42:33) - The Power of Human Words and Thoughts (1:48:20) - The Misunderstanding of Righteousness in Christianity (1:52:42) - Final Thoughts and Gratitude (1:55:06) For more updates, visit: http://www.brighteon.com/channel/hrreport  NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

If you've ever been told you're “too old,” your AMH is “too low,” your eggs are “gone,” or that donor eggs are your only option—you must listen to this episode.This is one of the most comprehensive, honest, science-based fertility conversations ever recorded.I sit down with one of the most innovative fertility specialists in the field to discuss breakthroughs that are changing possibilities for women at ANY age, including those with low ovarian reserve, recurrent loss, failed IVF cycles, or unexplained infertility.Today's guest is Dr. Zaher Merhi. Dr Merhi is the founder and the medical director of Rejuvenating Fertility Center (RFC). He is an internationally recognized fertility doctor, lecturer, editor, and grant reviewer. His training and faculty appointments included Albert Einstein College of Medicine/Montefiore Medical Center, NYU School of Medicine, and University of Vermont. He was a Professor at SUNY Downstate Health Sciences University and the Director of the Reproductive Endocrinology and Infertility (REI) Fellowship program (ACGME accredited). He is currently a Professor at Albert Einstein College of Medicine and Maimonides Medical Center in New York. He has 3 American Board certifications in OB/GYN, Reproductive Endocrinology and Infertility, and High-Complexity Laboratory Director (HCLD). Dr Merhi is one of the few Reproductive Immunologists in the country and is an active researcher with an interest in women older than 40 with Low Ovarian Reserve (low AMH or high FSH), Stem Cell ovarian rejuvenation, gentle stimulation IVF, natural IVF, and IVF without injectables. He was named “ONE OF THE TOP 2% SCIENTISTS IN THE WORLD.”For the first time publicly, you'll hear the truth about:✨ Environmental toxins are damaging eggs across generations✨ The rise of premature ovarian insufficiency✨ Microplastics found in the brain, ovaries & food supply✨ How inflammation drives aging, poor egg quality & failed implantation✨ Why diet absolutely impacts fertility (despite what many doctors say)✨ Cutting-edge ovarian rejuvenation options backed by published research✨ Stem-cell therapies are being used internationally to revive ovarian function✨ Why embryo testing is NOT black-and-white✨ The link between sperm DNA fragmentation & miscarriage✨ And why low AMH should NEVER be treated as an “infertility diagnosis”This conversation empowers couples with answers, hope, and real science—not fear.

Today marks the end of an incredible chapter. After five years, The Hydrogen Podcast signs off with one final episode—a deep reflection on the lessons, people, and progress that defined half a decade of global hydrogen evolution.From the early policy excitement to the hard economics of project delivery, host Paul Rodden takes listeners through the milestones, the missteps, and the breakthroughs that shaped both the show and the hydrogen market itself.

A revered name in modern Australian tennis, Casey Dellacqua is universally admired for her on-court achievements, commentary insights and humility through success. The West Australian-turned-Sydneysider played eight Grand Slam finals through her peak, claiming the French Open mixed doubles title in 2011. A famous partnership with Ash Barty delivered finals at all four Slams, but her name first went up in lights after a defeat of Amelie Mauresmo and a fourth-round run at AO 2008. Her singles career is oft underappreciated; Dellacqua progressed to at least the third round at every major. The former world No.26 stepped into Pod Lover Arena to tell Matt and Viv about the moment that flipped her career "on its head", victories she claimed through periods of physical and emotional turmoil and her current life with the "best job in the world".Listen to the full episode here. AusOpen.comiHeartApple PodcastsSpotify Host handles:@Viv_Christie@MattyATSee omnystudio.com/listener for privacy information.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a myriad of pivotal changes and advancements that have been shaping our industry.The competitive nature of acquisitions within the biopharma sector has been exemplified by recent strategic buyouts. Lundbeck's decision to outbid Alkermes for Avadel Pharmaceuticals highlights how companies are leveraging acquisitions to expand their capabilities and portfolios. Similarly, Pfizer's finalized acquisition of Metsera after a fierce bidding war with Novo Nordisk underscores the importance of securing valuable assets to strengthen positioning in critical therapeutic areas, such as obesity treatment, where demand continues to rise.Regulatory milestones remain at the heart of industry progress. Organon and Henlius's Poherdy recently received FDA approval as a biosimilar to Roche's Perjeta, offering a new treatment avenue for HER2-positive breast cancer patients. This approval is noteworthy as biosimilars play an essential role in oncology by providing similar efficacy to original biologics but at reduced costs, thereby enhancing healthcare affordability and accessibility. In Europe, the EMA's Committee for Medicinal Products for Human Use has endorsed several innovative drugs, including Otsuka's Dawnzera for hereditary angioedema and Lilly's Inluriyo for certain cancer types. These endorsements reflect the growing pipeline of treatments addressing both rare genetic disorders and widespread diseases.Merck & Co.'s acquisition of Cidara Therapeutics for $9.2 billion underscores a strategic pivot towards bolstering its antiviral portfolio. This deal is particularly significant given Cidara's promising influenza antiviral candidate, initially abandoned by Johnson & Johnson. In an era where infectious diseases pose ever-evolving challenges, Merck's investment in antivirals reflects a commitment to advancing therapeutic solutions in this crucial area.However, drug development's inherent uncertainties were highlighted by Bristol Myers Squibb and Johnson & Johnson's joint anticoagulant venture, which faced termination due to a Phase 3 trial failure. This setback emphasizes the challenges and risks entailed in developing novel therapeutics, particularly within high-stakes areas like cardiovascular health.Leadership changes can significantly impact corporate strategy, as seen with Bavarian Nordic following an unsuccessful private equity takeover attempt. Such shifts can influence investor confidence and reshape strategic directions.Investment trends also paint an optimistic picture for innovation within the sector. European life sciences investor Medicxi's successful raising of €500 million signifies robust financial support for biotech ventures. This influx of capital is vital for propelling early-stage research and development efforts across Europe, fostering breakthroughs in chronic and rare disease treatments.In terms of scientific innovation, advancements in bispecific antibody production through AI/ML-driven molecular design promise higher yields and enhanced quality. These technological innovations could revolutionize complex biologics manufacturing, potentially accelerating timelines and expanding therapeutic possibilities.The regulatory landscape is seeing significant activity as well. Notably, FDA officials introduced a novel pathway aimed at accelerating gene editing therapies' development and approval. By facilitating faster market entry for personalized medicines, this regulatory innovation could pave the way for treatments tailored to individual genetic profiles.Kyowa Kirin's collaboration with Kura Oncology reached a milestone with FDA approval for an oral medication targeting acute myeloidSupport the show

This week on the Mainly Moonology Podcast, we're diving into one of the most powerful astrological moments of the season. The Scorpio New Moon, sitting opposite Uranus and aligned with a rare Uranus–Neptune sextile, is bringing breakthrough energy that can feel emotional, liberating, and deeply spiritual all at once.I'm joined by fellow Aussie astrologer and author Vanessa Montgomery, and together we unpack what this week's cosmic weather really means for your manifesting, your emotional healing, and your ability to break free from old patterns.If you've been feeling ready to start again, release something heavy, or reconnect with your intuition, this episode will help you understand why the timing is so right.Listen now and use this New Moon to shift your life forward.Vanessa's website:https://astroallstarz.comIt's also the perfect moment to start thinking about 2026.The astrology of next year is big and bold, and if you want to stay aligned with every New Moon, Full Moon, eclipse, and key transit, make sure you've ordered your Moonology Diary.Get your Moonology Diary here:https://moonologydiary.comYour future self will thank you. Join the Mainly Moonology inner circle: https://moonmessages.com/magical––Follow Yasmin on socials:✨ Facebook: https://www.facebook.com/yasminbolandmoonology ✨ Instagram: https://www.instagram.com/moonologydotcom/––Mainly Moonology is a podcast for people looking to manifest their dream life leveraging the power of the moon. Tune in each week for accessible moon teachings, weekly readings, discussions about the Law of Attraction, and everything in between! Follow us for more.

This week on the Mainly Moonology Podcast, we're diving into one of the most powerful astrological moments of the season. The Scorpio New Moon, sitting opposite Uranus and aligned with a rare Uranus–Neptune sextile, is bringing breakthrough energy that can feel emotional, liberating, and deeply spiritual all at once.I'm joined by fellow Aussie astrologer and author Vanessa Montgomery, and together we unpack what this week's cosmic weather really means for your manifesting, your emotional healing, and your ability to break free from old patterns.If you've been feeling ready to start again, release something heavy, or reconnect with your intuition, this episode will help you understand why the timing is so right.Listen now and use this New Moon to shift your life forward.Vanessa's website:https://astroallstarz.comIt's also the perfect moment to start thinking about 2026.The astrology of next year is big and bold, and if you want to stay aligned with every New Moon, Full Moon, eclipse, and key transit, make sure you've ordered your Moonology Diary.Get your Moonology Diary here:https://moonologydiary.comYour future self will thank you. Join the Mainly Moonology inner circle: https://moonmessages.com/magical––Follow Yasmin on socials:✨ Facebook: https://www.facebook.com/yasminbolandmoonology ✨ Instagram: https://www.instagram.com/moonologydotcom/––Mainly Moonology is a podcast for people looking to manifest their dream life leveraging the power of the moon. Tune in each week for accessible moon teachings, weekly readings, discussions about the Law of Attraction, and everything in between! Follow us for more.

Neuroendocrine Tumors Explained: Symptoms, Treatments, and Breakthroughs with guest Dr. Pamela Kunz November 17, 2025 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Imagine an Anarcho-libertarian future wherein philosophy, reason, and science prevail. The cathedrals of corruption looming over every nation, governments have been replaced by direct democracy on an unhackable blockchain. And with the absence of the state, perverse economic incentives, monopolies, and dogma in healthcare. In that future, will traditional allopathic medicine and healthcare be relegated to the dustbin of history and replaced entirely by frequency medicine?That's the question I explore with Dr. Zulia Frost. I interview the woman behind the Flexbeam, my favorite red light therapy device, and Clinical Director of Recharge Health. She is a world-renowned expert in neuromodulation and photobiomodulation. Her professional profile is distinguished by three decades of direct patient care - blending Western medicine with traditional modalities (Chinese Medicine and Acupuncture) and rigorous academic training, providing an authoritative lens through which to examine the burgeoning field of wearable photobiomodulation.1:22 About Dr. Zulia Frost3:48 Will allopathic medicine be replaced by frequency medicine?6:35 A case for optimism about the future8:13 Her story - a wounded healer12:53 Traditional chinese medicine and acupuncture22:04 Red light therapy cofactors24:48 Recent red light therapy science30:16 Red light therapy for sleep33:06 Red light therapy vs S.A.D.36:09 Methylene blue and red light therapy39:24 Parenting questions: red light therapy for babies (and boobies)?45:58 My experience with the FlexBeam51:45 The Recharge Health community53:15 Convincing the stubborn (and suffering) to try alternative medicine?58:06 Rant on subscription-servicization of Biohacking productsRead

In this reflection, I explore what feels like the necessity of an unfortunate decision.    Supporting themes: The classroom; Authenticity within context; Accessible authenticity vs inaccessible authenticity vs entitled accessibility; Authenticity as an inner experience or an outer experience; Breakthroughs in my grief (clarity); Therapy; Black spaces; and much more.   Typology: INTJ8

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

PREVIEW Brendan Weichert comments on the US-China AI race. While executives suggest China might win, the US has restricted sales of high-end chips, fearing misuse. China claims chip breakthroughs are imminent. Both sides are developing rapidly: China appears stronger in robotics, while the US maintains a lead in AI software development. Guest: Brendan Weichert.

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the central system of record for biotech R&D, but uses AI agents to assist scientists to help fix this broken system. Sajith details the roadblocks that impede drug development and approval, the “dot com” bust occurring in biotech, and how AI agents and simulation can help scientists experiment faster. Plus, they talk about China's competitive rise in the pharma space, and the unique challenges of building an interdisciplinary culture that merges the worlds of science and software.  Rebuild biotech for the AI era - Sajith Wickramasekara Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @sajithw | @benchling Chapters: 00:00 – Sajith Wickramasekara Introduction 00:38 – Origin and Mission of Benchling 02:08 – The Drug Development Process 03:49 – Current State of the Biotech industry  08:46 – AI's Role in Biotech 16:14 – Benchling AI and Its Impact 18:36 – The Future of AI in Biotech  26:28 – Debunking AI Drug Discovery Myths 28:50 – Data's Role in Biotech 29:35 – The Importance of Tools in Pharma 31:28 – AI's Impact on Scientific Research 34:55 – Building a Biotech Company 40:18 – Interdisciplinary Collaboration in Biotech  43:06 – Tech and Biotech: Learning from Each Other 48:16 – Conclusion

WHEN FACTS & INTERPRETATIONS SEPARATE-Most confusion comes from mixing what happened with what we think it means. Helping clients tell those apart creates immediate freedom and responsibility. Key Takeaways Facts are neutral; interpretations give them emotional weight. This distinction restores agency and reduces blame. Naming facts grounds emotion in truth. Action Guide Ask in your next session, “What's the fact, and what's the meaning you added?” Notice how quickly clarity returns. Read the Life Coach Blog Become a Life Coach Join the Coaching FB Community —> HERE Find me @coachlauramalone on IG —> HERE Your 5 star review on Apple Podcasts means a ton✨

In this episode, we sit down with the new book Running Breakthroughs author Floris Gierman to explore what truly drives joy, consistency, and long-term progress in running. Floris shares the patterns he's uncovered after years of conversations with athletes, coaches, and researchers—stories of everyday runners who transformed their lives through simple habits, sustainable training, and a kinder relationship with themselves. We talk about why self-compassion is one of the most overlooked performance tools, how slowing down can actually speed you up, and why being present in the moment matters more than chasing the perfect workout. Floris opens up about the breakthrough stories that changed him, including moments that reshaped his definition of success both on and off the trail. If you've ever struggled with plateaus, burnout, or being too hard on yourself, this conversation offers practical tools—and inspiring reflections—to help you fall in love with running all over again.  Episode Sponsors Janji, Use code TRAILRUNNER for 10% off NEW!  MudGear Socks - Get a special discount by clicking the link Get the NEW "1 > 0" running hat HERE.  Limited supply.... and they will be on sale for 24 hours during Black Friday, November 21

Sam Shepard, a physicist and prolific inventor, joins the show to share his extraordinary personal journey of facing a rare and aggressive bone blood cancer diagnosis. Motivated by a desire to find answers where conventional medicine offered little hope, Sam recounts how his scientific curiosity and research skills led him to explore natural solutions, ultimately resulting in unexpected remission and inspiring him to advocate for integrative approaches to cancer treatmentSam Shepard recounts his career in physics and innovative projects—such as developing energy solutions for NASA's lunar missions and advancing battery technology for drones—showcasing his engineering mindset and passion for solving complex problems. He discusses the formidable challenges of interplanetary radiation exposure and how his curiosity led to broader research on disease and technology, ultimately interweaving his professional and personal lives as these pursuits became deeply relevant to his health.A sudden diagnosis of polycythemia vera—a rare and terminal bone blood cancer—changes Sam's life trajectory. With no established protocols, a grim prognosis, and exhausting cycles of medical intervention, Sam turns to research, considering whether there might be something in nature that resists cancer. His investigation, powered by access to large scientific databases, lands on five animals rarely afflicted by cancer, with a commonality: a molecule called astaxanthin, sourced from a unique algae species.Sam methodically cultivates the algae, consumes astaxanthin, and documents improvements in his health and bloodwork. Testing higher doses, he observes greater normalization and ultimately achieves what his doctors call a “miraculous remission.” Sharing his discovery, Sam supports family and friends with dire cancer diagnoses using this natural compound—later patented as velasta—and witnesses further dramatic recoveries, including a woman's complete remission from metastatic cancer documented against her medical prognosis.The conversation culminates in broader lessons, as Sam describes national presentations of his findings and ensuing legal battles, signaling the skepticism and systemic resistance faced by natural medicine advocates. Importantly, the episode details the powerful anti-inflammatory and antioxidant properties of astaxanthin/velasta, how it helps protect cells and the immune system, and why making such knowledge public is sometimes vital for innovators. Dr. Karl concludes by thanking Sam, reinforcing the show's mission of education and hope for those battling cancer—and reminding listeners that integrative science can transform even the bleakest diagnoses.Sam Shepard, a physicist and inventor, shares his journey of overcoming a terminal bone blood cancer using astaxanthin, a natural compound sourced from algae.Inspired by animals rarely affected by cancer, Sam investigates and cultivates astaxanthin, documenting significant improvements and ultimately experiencing remission after increasing his intake.Sam supports other late-stage cancer patients with his discovery, witnessing remarkable recoveries, which leads to a patented supplement called velasta.The episode delves into the molecular science behind astaxanthin's powerful anti-inflammatory and antioxidant effects in disrupting cancer growth and supporting cellular health.Dr. Karlfeldt and Sam discuss systemic resistance to natural medical approaches, emphasizing hope, education, and integrative science for patients seeking alternatives beyond conventional treatments_____________________Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Hi there, and welcome into Scheduling Fate and your Daily Vibes — a space to pause, reflect, and realign.As we step into today's energy, the Leo Moon makes one last fiery statement before handing things over to the Virgo Moon — bringing both emotional breakthroughs and the clarity needed to move forward with grace.✨ Astrology Highlights:

- Announcements and Interviews on Brighteon (0:00) - Health News and Canadian Government's Actions (4:26) - China's Research on Grape Seed Extract (10:40) - Tour of the New Lab and Health Ranger Store (22:29) - Economic Depression and Living Broke (41:19) - Canadian Government's Mass Extermination Plans (1:09:33) - Interview with John Roy from Dawson Knives (1:19:58) - American-Made Manufacturing and Innovation (1:21:24) - Pro Cut Steel and Frog Lube (1:22:43) - Black Friday Sale and Economic Challenges (1:24:57) - Innovations and Future Plans (1:36:51) - Customer Feedback and Design Features (1:45:01) - Supply Chain and Regulatory Challenges (1:50:31) - Commitment to Quality and Craftsmanship (1:50:51) - Future Innovations and Technological Advancements (1:51:30) - Customer Engagement and Marketing Strategies (1:58:09) - Final Thoughts and Future Plans (2:04:42) - America's Health Crisis and the Role of Big Pharma (2:05:31) - Economic and Social Collapse Scenarios (2:16:54) - Military and Police State Preparedness (2:35:21) - AI and Robotics in Warfare (2:40:01) - Economic and Social Implications of Collapse (2:42:37) - Technocracy and Universal Basic Income (2:51:04) - Globalist Plans and Resistance (2:58:06) - Economic and Political Challenges (3:02:29) - Preparation and Survival Strategies (3:02:45) - Black Friday Sale and Health Ranger Store (3:02:58) For more updates, visit: http://www.brighteon.com/channel/hrreport  NaturalNews videos would not be possible without you, as always we remain passionately dedicated to our mission of educating people all over the world on the subject of natural healing remedies and personal liberty (food freedom, medical freedom, the freedom of speech, etc.). Together, we're helping create a better world, with more honest food labeling, reduced chemical contamination, the avoidance of toxic heavy metals and vastly increased scientific transparency. ▶️ Every dollar you spend at the Health Ranger Store goes toward helping us achieve important science and content goals for humanity: https://www.healthrangerstore.com/ ▶️ Sign Up For Our Newsletter: https://www.naturalnews.com/Readerregistration.html ▶️ Brighteon: https://www.brighteon.com/channels/hrreport ▶️ Join Our Social Network: https://brighteon.social/@HealthRanger ▶️ Check In Stock Products at: https://PrepWithMike.com

316 - What if the secret to unstoppable confidence wasn't about never failing but being willing to feel embarrassed along the way? In this week's conversation, Heather and Susie unpack what it really takes to believe in yourself, even when the road gets rocky. Literally.What to Listen ForThe powerful mindset shift that helped Susie finally believe in herselfWhy confidence comes after action, not before itHow a muddy 4x4 adventure turned into the ultimate business metaphorThe question Heather asks every struggling photographerWhy being willing to feel embarrassed can make you unstoppableHow “I didn't really try” thinking secretly sabotages your progressThe difference between disappointment and failure (and why it matters)The real reason your confidence plateaus and how to fix itConfidence isn't a one-and-done achievement. It's a practice. And sometimes, the biggest leaps forward come from the moments that feel the most uncomfortable. If you've been waiting to “feel ready” before raising your prices, booking higher-end clients, or finally going full-time—this episode is your permission slip to do it anyway.Listen now, take messy action, and see what happens when you stop letting fear drive.Coach week starts TODAY!  Join us here: https://www.freedomfocusformula.com/coachweekMore ResourcesNicole's Instagram: @nicolebegleyofficialHeather's Flourish Academy - https://flourishacademy.mykajabi.com/Master the craft of pet photography at the Hair of the Dog Academy – www.hairofthedogacademy.comFreedom Focus Formula – www.freedomfocusformula.comElevate – www.freedomfocusformula.com/elevateCommercial Pet Photography Academy – www.hairofthedogacademy.com/commercialJoin Us for Coach Week: 3 Days of Live Coaching and Breakthroughs to Help You Unlock Your Photography Business PotentialNovember 11th, 12th, 13th at 2 PM EST DailyJOIN THE PARTY: Connect with us on Instagram Explore valuable pet photography resources here Discover effective pricing and sales strategies for all portrait photographers. Ready to grow your business? Elevate helps you do just that. Check out our recommended gear and favorite books.

November 11, 2025 | What is the next modality to focus on in the next 10 years? For Bahija Jallal, CEO of Immunocore, it would be T-cell engagers. In this episode of The Chain, host Rakesh Dixit speaks with Jallal on the potential advantages of bispecific T-cell engager therapy versus T-cell receptor therapy, biggest anticipated changes in drug discovery and development in the next 10 years, and how AI is going to impact the next generation of scientists. Plus, Jallal shares her experiences as the previous president of MedImmune and at AstraZeneca, what her most rewarding project was, and the transformations and achievements that occurred under her leadership. Links from this episode:  Immunocore 

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

Chinese Rocket Failure: Galactic Energy's Ceres 1 rocket faced a setback with its second-ever launch failure, as the upper stage shut down prematurely, resulting in the loss of three satellites. The company is investigating the cause while maintaining a respectable success rate of over 90% across 22 missions.Black Hole Mystery Solved: Astronomers have unraveled the enigma of an "impossible" black hole merger that produced a black hole within the upper stellar mass gap. New simulations incorporating magnetic fields revealed that material was ejected before the merger, allowing the resulting black hole to fit into this previously unexplained range.Rocket Lab's Neutron Delay: Rocket Lab has postponed the first launch of its Neutron rocket to 2026 to ensure a successful debut. The decision reflects a commitment to thorough testing over adhering to an aggressive schedule, emphasizing the importance of a reliable first flight for their next-generation reusable rocket.Filming in Space: The upcoming romantic comedy "I See You" aims to be the first western film to shoot scenes in low Earth orbit, with former NASA astronaut Scott Kelly advising the project. This ambitious endeavor follows the Russian film "The Challenge," which was the first feature film with scenes shot in space.Asteroid Monitoring: NASA is tracking asteroid 2024 YR4, which poses no threat to Earth but has a small chance of impacting the Moon in 2032. This potential impact presents a unique opportunity for scientific observation, allowing researchers to study lunar surface composition and the physics of high-velocity impacts.For more cosmic updates, visit our website at astronomydaily.io. Join our community on social media by searching for #AstroDailyPod on Facebook, X, YouTubeMusic, TikTok, and our new Instagram account! Don't forget to subscribe to the podcast on Apple Podcasts, Spotify, iHeartRadio, or wherever you get your podcasts.Thank you for tuning in. This is Anna and Avery signing off. Until next time, keep looking up and exploring the wonders of our universe.✍️ Episode ReferencesCeres 1 Launch Failure[Galactic Energy](https://www.galacticenergy.com/)Black Hole Merger Study[NASA](https://www.nasa.gov/)Rocket Lab Neutron Update[Rocket Lab](https://www.rocketlabusa.com/)Filming in Space[Space.com](https://www.space.com/)Asteroid 2024 YR4 Tracking[NASA](https://www.nasa.gov/)Become a supporter of this podcast: https://www.spreaker.com/podcast/astronomy-daily-space-news-updates--5648921/support.Sponsor Details:Ensure your online privacy by using NordVPN. To get our special listener deal and save a lot of money, visit www.bitesz.com/nordvpn. You'll be glad you did!Sponsor Details:Ensure your online privacy by using NordVPN. To get our special listener deal and save a lot of money, visit www.bitesz.com/nordvpn. You'll be glad you did!Become a supporter of Astronomy Daily by joining our Supporters Club. Commercial free episodes daily are only a click way... Click HereThis episode includes AI-generated content.

Susanne Kogut, President of Petco Love, talks about their inspiring mission to help pets and their people. Learn how Petco Love supports dog cancer research, funds treatment for pet parents in need, and even pioneers groundbreaking initiatives like lost pet facial recognition and free vaccination drives. Topics Covered: • Why the Petco Foundation became Petco Love • Petco Love Lost: The lost-and-found pet database revolution • 1 million free vaccines for dogs and cats: How it's saving lives • $18 million invested in dog cancer research and subsidized treatments • Groundbreaking immunotherapy and ultrasound research for canine cancer • How you can support Petco Love's mission Donate: Support Petco Love's life-saving initiatives by donating at your local Petco store, online at https://www.petcolove.org, or during checkout at Petco's online store. Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos: https://www.youtube.com/watch?v=WEvFhsC_TyY Related Links: Petco Love: https://petcolove.org/ Petco Love Lost: https://petcolove.org/lost/ Petco Love Care vaccination program: https://petcolove.org/care/ Morris Animal Foundation: https://www.morrisanimalfoundation.org/ Mosby Foundation: https://themosbyfoundation.org/programs/ FACE Foundation: https://face4pets.org/ Charlottesville-Albemarle SPCA: https://www.caspca.org/ Chapters: 00:00 Introduction 01:15 - From Petco Foundation to Petco Love 03:00 - Love Lost: A New Solution for Lost Pets 06:30 - Free Vaccination Drive for Preventable Diseases 09:15 - Petco Love's $18 Million Dog Cancer Initiative 12:00 - Cutting-Edge Canine Cancer Research Highlights 14:30 - Immunotherapy Vaccines for Dogs with Lymphoma 16:00 - Breakthroughs in Focused Ultrasound Technology 18:45 - Subsidized Cancer Treatment Programs at Top Universities 21:00 - How Pet Parents Can Access Petco Love Funds 23:30 - Susanne's Journey: From Corporate Attorney to Animal Advocate 27:00 - How You Can Support Petco Love's Mission Get to know Susanne Kogut: https://www.dogcancer.com/people/susanne-kogut/ For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textDr. Koren joins Kevin Geddings to report live from the American Heart Association meeting in New Orleans with fresh results on LDL lowering, prevention, and the future of gene editing for cholesterol. They discuss the excitement of big meetings like the AHA and how results can even surprise the investigators that were working on a study.Note: Dr. Koren refers to CRISPR Therapeutics, a company developing gene-based cholesterol lowering technologies. CRISPR-Cas9 is also the general name of a gene editing technique.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Have you ever felt burned out from hunting—or worried the thrill is starting to fade? You're not alone. In this episode of Gun Talk Hunt, host Kevin “KJ” Jarnagin is joined by Whiskey & Windage podcast hosts Mike Perkins and Matt Brass, along with Gun Talk's Chris Cerino, for a raw and honest conversation about losing—and rediscovering—the drive to hunt.This Gun Talk Hunt is brought to you by Savage Arms, Remington Ammo, Range Ready Studios, and ZEISS.About Gun Talk HuntGun Talk Media's Gun Talk Hunt, with Kevin “KJ” Jarnagin, pairs decades of experience with today's latest tools and technology to help you succeed in the field. Whether it runs or flies - no matter what game you pursue - Gun Talk Hunt is a multi-platform podcast that gives today's hunters a voice in the digital world.For more content from Gun Talk Media, visit guntalk.com or subscribe on YouTube, Rumble, Facebook, Instagram, and X. Catch First Person Defender on the new Official FPD YouTube channel. Watch Gun Talk Nation on its new YouTube channel. Catch Gun Talk Hunt on the new dedicated YouTube Channel. Listen to all Gun Talk Podcasts with Spreaker, iHeart, Apple Podcasts, Spotify or wherever you find podcasts.Copyright ©2025 Freefire Media, LLCGun Talk Hunt 11.08.25Become a supporter of this podcast: https://www.spreaker.com/podcast/gun-talk--6185159/support.

Dr. Ben, Dr. Tricia Scaglione and Patrick Lynch of American Tinnitus Assocation (ATA) discuss the latest in tinnitus research, advocacy, and patient support. Hear how ATA funds studies, elevates awareness, and connects people with evidence-based care like sound therapy and CBT. Learn practical tips, trusted resources, and ways to get involved in advancing hearing health.Get started with Treble Health:Schedule a complimentary telehealth consultation: treble.health/free-telehealth-consultation Take the tinnitus quiz: https://treble.health/tinnitus-quiz-1Download the Ultimate Tinnitus Guide: 2024 Edition: https://treble.health/tinnitus-guide-2024

Dr. Jim Heid spent 30 years practicing full-spectrum family medicine, delivering babies, staying up all night, and walking with patients through every season of life. But when burnout hit and identity questions bubbled to the surface, he realized it was time to do the thing himself. Now a coach helping others rediscover their deepest sense of purpose, Jim shares how he transitioned out of traditional medicine, what he's learned about imposter syndrome and storytelling, and why cycling has become a metaphor for personal growth, celebration, and sustainable success. In this wide-ranging episode with Stacey Lauren, you'll hear about: - What it really means to coach the person, not the problem - How Jim helps people reconnect with who they are (beyond their job title) - The hidden cost of ignoring your own wisdom - Why hydration, spreadsheets, and community matter more than you think - A new definition of doing the thing... without the burnout Learn more: https://jimheidcoaching.com Connect on Instagram: @repurposemanjim 00:00 — From family doctor to life coach: Jim's career pivot 07:35 — “Coach the person, not the problem” — birth stories + breakthrough coaching 14:10 — Why identity struggles show up post-retirement 25:00 — Cycling, burnout, and celebrating the hilltops 39:40 — Imposter syndrome, storytelling, and “just doing the thing” YouTube: https://youtu.be/aG-iw_P2WdU Apple Podcasts: https://podcasts.apple.com/us/podcast/from-delivering-babies-to-breakthroughs-dr-jim-heid/id1618590178?i=1000735897389 Spotify: https://open.spotify.com/episode/2AT6XtKqUNma3wFV0hLSmX

Send us a textYou ask a powerful question, the room goes quiet, and your stomach tightens—should you jump in? We pull back the curtain on why that silent pause is often the most important moment in a coaching session and how to trust it instead of rushing to fill it. When a client doesn't answer right away, it isn't a dead end; it's the mind at work, reaching past automatic responses to find what's real.We share a clear, practical approach to holding space: breathe, relax your body, and invite the client to take their time. Rather than stacking more words, protect the quiet and watch for subtle cues that thinking is happening. You'll hear how this played out on a recent certification call when a coach, after a reflective pause, realized she'd been taking aligned actions but never gave herself credit. That single insight shifted her energy—and the whole room's—proving that silence can spark momentum, clarity, and confidence.Along the way, we unpack why coaches feel pressure to talk (awkwardness, fear of emptiness, a habit of fixing) and offer mindset shifts that move you from performance to presence. The best insights come from your client, not from you, and the pause is where they claim them. We close by teeing up the next breakthrough: stopping the fixer reflex and guiding discovery instead, so sessions become lighter, deeper, and far more impactful.If this resonated, follow the show, share it with a coach who needs this reminder, and leave a quick review telling us what changes when you trust the pause.Interested in elevating your coaching skills and accelerating your clients' growth? Become a Certified Life Coach!Join the waitlist:https://www.modernleadership.us/mastery

STUCKNESS ISN'T FAILURE— When clients loop, defend, or go quiet, they're not resisting you—they're protecting themselves. Your job isn't to push; it's to stay calm and create safety until their system can settle and see again. Key Takeaways Stuckness often signals pain, not rebellion. Silence and curiosity regulate the moment better than pressure. Presence builds trust that allows insight to emerge naturally. Action Guide When a client gets stuck, wait five full breaths before speaking. Let the stillness do its work. Read the Life Coach Blog Become a Life Coach Join the Coaching FB Community —> HERE Find me @coachlauramalone on IG —> HERE Your 5 star review on Apple Podcasts means a ton✨

This week on Heart Doc VIP, Dr. Joel Kahn reviews the latest advances in treating aortic and mitral valve disease. While prevention remains the cornerstone of heart health, not all valve conditions can be avoided — and many require medical or surgical intervention beyond lifestyle changes. Dr. Kahn brings you up to date on the newest valve therapies and what they mean for patients. Short topics this week include semaglutide's effects on the heart, the connection between gum disease and brain health, the media's role in shaping medical news, the healthiest antidote to sitting, stem cells for heart repair, the value of calcium scoring, and how fruits and vegetables can improve sleep.  Dr. Kahn also invites listeners to explore catchbio.com — the first cancer screening and prevention risk app. Use code DRKAHN to save 25% on the annual subscription. And don't miss out on high-quality EVOO from getfreshdrkahn.com — just $1 for shipping!

Steve Moss is a high-level boulderer and the co-founder of a brewery and pizzeria in Spokane, WA. We talked about finding climbing at age 24, his breakthrough season climbing three V12s in less than two weeks at age 40, why discomfort helps us grow, his training routine for the past year, building a successful brewery and pizzeria from the ground up, what matters most in climbing, gratitude for life, the connections we make through climbing, and much more.The Nugget Training App | 14 Day Free Trialtraining.thenuggetclimbing.comThe GRINDS Program | FREE Finger Training PDFthenuggetclimbing.com/grindsThe NUG | Portable Hangboardfrictitiousclimbing.com/products/the-nugRúngne (Chalk & Apparel)rungne.info/nuggetUse code “NUGGET" for 10% off and "SHIPPINGNUGGETS" for free shipping.Mad Rock (Shoes & Crash Pads)madrock.comUse code “NUGGET10” at checkout for 10% off your next order.Become a Patron:patreon.com/thenuggetclimbingShow Notes:  thenuggetclimbing.com/episodes/steve-mossNuggets:(00:00:00) – Intro(00:02:21) – Steve's climbing origin story(00:07:30) – Life before climbing(00:09:58) – His wife(00:14:27) – Leavenworth(00:18:41) – A resurgence of stoke(00:23:37) – Passion & challenge(00:26:36) – Why discomfort is beneficial(00:34:21) – Building the brewery(00:52:31) – Brewing beer(00:56:56) – Steve's nephew(01:04:11) – Double V12 day(01:11:46) – Gratitude(01:14:37) – Protein & breakthroughs(01:20:51) – Bodyweight(01:24:17) – Crimping(01:27:42) – The hardest part of training(01:36:39) – Steve's training(02:03:30) – 455 V-point day(02:20:31) – Century bike ride(02:21:49) – Advice for a young Steve Moss(02:27:48) – Baseball(02:29:19) – The people(02:36:21) – What's next